CTMX (CytomX Therapeutics) Ending Cash Position: $30.36 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTMX CytomX Therapeutics Inc CTMX
36 GF Score
Price $3.62
GF Value $0.28
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CytomX Therapeutics Ending Cash Position?

CytomX Therapeutics CTMX -1.23% 36 Ending Cash Position is $30.36 Mil as of Mar. 2026. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review.

CytomX Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 was $30.36 Mil.

CytomX Therapeutics's quarterly Ending Cash Position declined from Sep. 2025 ($35.21 Mil) to Dec. 2025 ($14.19 Mil) but then increased from Dec. 2025 ($14.19 Mil) to Mar. 2026 ($30.36 Mil).

CytomX Therapeutics's annual Ending Cash Position increased from Dec. 2023 ($18.09 Mil) to Dec. 2024 ($39.08 Mil) but then declined from Dec. 2024 ($39.08 Mil) to Dec. 2025 ($14.19 Mil).

CytomX Therapeutics Ending Cash Position Related Terms

CytomX Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for CytomX Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytomX Therapeutics Ending Cash Position Chart

CytomX Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 206.45 194.57 18.09 39.08 14.19

CytomX Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.63 50.07 35.21 14.19 30.36
CTMX
36GF Score
CytomX Therapeutics Inc CTMX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytomX Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

CytomX Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=39.079+-24.885
=14.19

CytomX Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=14.194+16.161
=30.36

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $30.36 Mil mean?
CytomX Therapeutics (CTMX) has a Ending Cash Position of $30.36 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on CytomX Therapeutics and its competitors.
Is CytomX Therapeutics' Ending Cash Position too high?
CytomX Therapeutics' current Ending Cash Position is $30.36 Mil. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Ending Cash Position compare to ALLO and XOMA?
CytomX Therapeutics' Ending Cash Position of $30.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on CytomX Therapeutics and its competitors. CytomX Therapeutics's current Ending Cash Position is $30.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.62 — trading 1192.9% above its estimated fair value. The current Ending Cash Position is $30.36 Mil. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Ending Cash Position is $30.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytomX Therapeutics (CTMX) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of $3.62 is trading 1192.9% above its estimated GF Value™ of $0.28. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for CTMX:

  • Ending Cash Position: $30.36 Mil
  • GF Value™: $0.28 vs. price of $3.62 (1192.9% above fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CytomX Therapeutics Business Description

Other Exchanges 6C1:Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score

Get the complete analysis for CTMX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.62
Price
$0.28
GF Value